Managing Refractory Ocular Surface Disease With Cryopreserved Amniotic Membrane Therapy
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membrane therapy can effectively treat complex cases of refractory ocular surface disease by addressing multiple contributing factors simultaneously, as demonstrated in a patient aged 81 years with diabetes, eczema, and severe blepharitis who showed significant epithelial improvement after comprehensive treatment.
Cryopreserved vs Dehydrated Amniotic Membranes
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membranes preserve the critical heavy chain hyaluronic acid and pentaxin-3 molecules that deliver anti-inflammatory and antiscarring properties, making them significantly more effective than dehydrated versions for regenerating the ocular surface.
Advancing Dry Eye Management: Integrating Regenerative Therapies Into Optometric Practice
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how amniotic membranes can be effectively incorporated into optometric practice as a “reset button” treatment for the full continuum of ocular surface disease severity, from mild to severe cases. This offers patients an alternative to multiple eye drops while being efficiently applied during regular clinic visits.